On May 2, 2019, Scott L. Glenn resigned from the Board of Directors of Evoke Pharma, Inc. In addition, the Board has determined to reassign Todd Brady, M.D., Ph.D. from Class I of the Board to Class II of the Board and, accordingly, Dr. Brady will stand for re-election at the 2021 Annual Meeting of Stockholders. Further, the Board appointed Dr. Brady as a member of the Audit Committee to replace Mr. Glenn as an Audit Committee member.